Together, these results outline a novel functional role for aberrant IFNγ producing immune dysfunction in promoting IBD-CRC via modulation of IDO1-mediated tryptophan metabolism and suggest potential therapeutic avenues for targeting human disease. The gene discussed is IFNG; the disease is inflammatory bowel disease.